95 related articles for article (PubMed ID: 21521022)
1. An approach to identifying preclinical biomarkers of susceptibility to drug-induced toxicity.
Lin WJ; Chen JJ
Pharmacogenomics; 2011 Apr; 12(4):493-501. PubMed ID: 21521022
[TBL] [Abstract][Full Text] [Related]
2. Identification of drug-induced toxicity biomarkers for treatment determination.
Lu TP; Chen JJ
Pharm Stat; 2015; 14(4):284-93. PubMed ID: 25914330
[TBL] [Abstract][Full Text] [Related]
3. Biomarker classifiers for identifying susceptible subpopulations for treatment decisions.
Lin WJ; Chen JJ
Pharmacogenomics; 2012 Jan; 13(2):147-57. PubMed ID: 22188363
[TBL] [Abstract][Full Text] [Related]
4. Genomic and genetic biomarkers of toxicity.
Mendrick DL
Toxicology; 2008 Mar; 245(3):175-81. PubMed ID: 18206287
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional profiling to identify biomarkers of disease and drug response.
Mendrick DL
Pharmacogenomics; 2011 Feb; 12(2):235-49. PubMed ID: 21332316
[TBL] [Abstract][Full Text] [Related]
6. Rationalizing Secondary Pharmacology Screening Using Human Genetic and Pharmacological Evidence.
Deaton AM; Fan F; Zhang W; Nguyen PA; Ward LD; Nioi P
Toxicol Sci; 2019 Feb; 167(2):593-603. PubMed ID: 30346593
[TBL] [Abstract][Full Text] [Related]
7. Availability of pharmacogenetic and pharmacogenomic information in anticancer drug monographs in France: personalized cancer therapy.
Albertini L; Siest G; Jeannesson E; Visvikis-Siest S
Pharmacogenomics; 2011 May; 12(5):681-91. PubMed ID: 21619430
[TBL] [Abstract][Full Text] [Related]
8. Whole-genome sequencing in pharmacogenetics.
Urban TJ
Pharmacogenomics; 2013 Mar; 14(4):345-8. PubMed ID: 23438878
[No Abstract] [Full Text] [Related]
9. A new proposal for randomized start design to investigate disease-modifying therapies for Alzheimer disease.
Zhang RY; Leon AC; Chuang-Stein C; Romano SJ
Clin Trials; 2011 Feb; 8(1):5-14. PubMed ID: 21335586
[TBL] [Abstract][Full Text] [Related]
10. Sieving treatment biomarkers from blood gene-expression profiles: a pharmacogenomic update on two types of multiple sclerosis therapy.
Goertsches RH; Zettl UK; Hecker M
Pharmacogenomics; 2011 Mar; 12(3):423-32. PubMed ID: 21449680
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers of disease activity in multiple sclerosis.
Graber JJ; Dhib-Jalbut S
J Neurol Sci; 2011 Jun; 305(1-2):1-10. PubMed ID: 21463872
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomic biomarkers for personalized medicine.
Chen JJ; Lin WJ; Chen HC
Pharmacogenomics; 2013 Jun; 14(8):969-80. PubMed ID: 23746190
[TBL] [Abstract][Full Text] [Related]
13. Promise of new translational safety biomarkers in drug development and challenges to regulatory qualification.
Sistare FD; DeGeorge JJ
Biomark Med; 2011 Aug; 5(4):497-514. PubMed ID: 21861671
[TBL] [Abstract][Full Text] [Related]
14. Metabolomics for early detection of drug-induced kidney injury: review of the current status.
Boudonck KJ; Rose DJ; Karoly ED; Lee DP; Lawton KA; Lapinskas PJ
Bioanalysis; 2009 Dec; 1(9):1645-63. PubMed ID: 21083109
[TBL] [Abstract][Full Text] [Related]
15. Advances in the development of genetic markers for the diagnosis of disease and drug response.
Halapi E; Hakonarson H
Expert Rev Mol Diagn; 2002 Sep; 2(5):411-21. PubMed ID: 12271813
[TBL] [Abstract][Full Text] [Related]
16. Reducing false positive findings in statistical analysis of pharmacogenomic biomarker studies using high-throughput technologies.
Matsui S
Curr Drug Saf; 2006 May; 1(2):135-41. PubMed ID: 18690924
[TBL] [Abstract][Full Text] [Related]
17. Molecular profiling approaches for identifying novel biomarkers.
Bailey WJ; Ulrich R
Expert Opin Drug Saf; 2004 Mar; 3(2):137-51. PubMed ID: 15006720
[TBL] [Abstract][Full Text] [Related]
18. Advances in pharmacogenomics technologies.
Bhasker CR; Hardiman G
Pharmacogenomics; 2010 Apr; 11(4):481-5. PubMed ID: 20350126
[TBL] [Abstract][Full Text] [Related]
19. Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury.
Waring WS; Moonie A
Clin Toxicol (Phila); 2011 Oct; 49(8):720-8. PubMed ID: 21970770
[TBL] [Abstract][Full Text] [Related]
20. Sample size calculation through the incorporation of heteroscedasticity and dependence for a penalized t-statistic in microarray experiments.
Hirakawa A; Hamada C; Yoshimura I
J Biopharm Stat; 2012; 22(2):260-75. PubMed ID: 22251173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
